{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:04:52Z","timestamp":1773288292629,"version":"3.50.1"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.7759\/cureus.83455","type":"journal-article","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T15:52:57Z","timestamp":1746373977000},"source":"Crossref","is-referenced-by-count":1,"title":["Proteinuria in Alport Syndrome: Treatment With Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors"],"prefix":"10.7759","author":[{"given":"Gautam","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhawna","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pallavi","family":"Shirsat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Sonavane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000001063","article-title":"Alport syndrome: an update","volume":"34","author":"Savige J","year":"2025","unstructured":"Savige J. Alport syndrome: an update. Curr Opin Nephrol Hypertens. 2025, 34:206-11. 10.1097\/MNH.0000000000001063","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.akdh.2024.02.004","article-title":"Alport syndrome","volume":"31","author":"Chavez E","year":"2024","unstructured":"Chavez E, Goncalves S, Rheault MN, Fornoni A. Alport syndrome. Adv Kidney Dis Health. 2024, 31:170-9. 10.1053\/j.akdh.2024.02.004","journal-title":"Adv Kidney Dis Health"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport syndrome: achieving early diagnosis and treatment","volume":"77","author":"Kashtan CE","year":"2021","unstructured":"Kashtan CE. Alport syndrome: achieving early diagnosis and treatment. Am J Kidney Dis. 2021, 77:272-9. 10.1053\/j.ajkd.2020.03.026","journal-title":"Am J Kidney Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","unstructured":"KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024, 105.S117-314. 10.1016\/j.kint.2023.10.018","journal-title":"Kidney Int"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf051","article-title":"SGLT2 inhibitors in CKD: are they really effective in all patients?","author":"Romagnani P","year":"2025","unstructured":"Romagnani P. SGLT2 inhibitors in CKD: are they really effective in all patients?. Nephrol Dial Transplant. 2025, 10.1093\/ndt\/gfaf051","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071815","article-title":"Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, alport syndrome, and FSGS: a case series to better plan a large-scale study","volume":"10","author":"Boeckhaus J","year":"2021","unstructured":"Boeckhaus J, Gross O. Sodium-glucose cotransporter-2 inhibitors in patients with hereditary podocytopathies, alport syndrome, and FSGS: a case series to better plan a large-scale study. Cells. 2021, 10:10.3390\/cells10071815","journal-title":"Cells"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae180","article-title":"Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport","volume":"40","author":"Gross O","year":"2025","unstructured":"Gross O, Boeckhaus J, Weber LT, et al.. Protocol and rationale for a randomized controlled SGLT2 inhibitor trial in paediatric and young adult populations with chronic kidney disease: DOUBLE PRO-TECT Alport. Nephrol Dial Transplant. 2025, 40:679-87. 10.1093\/ndt\/gfae180","journal-title":"Nephrol Dial Transplant"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/361888-proteinuria-in-alport-syndrome-treatment-with-sodium-glucose-co-transporter-2-sglt2-inhibitors","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T15:52:58Z","timestamp":1746373978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/361888-proteinuria-in-alport-syndrome-treatment-with-sodium-glucose-co-transporter-2-sglt2-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,4]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.83455","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,4]]}}}